Cara Partners — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cara Partners is a long-established, Ireland-based manufacturer of a specific botanical Active Pharmaceutical Ingredient (API): a standardized Ginkgo Biloba extract. As part of the Schwabe Group, it leverages Ireland's EU membership and skilled workforce to produce and supply this ingredient globally. The company operates in a niche but established segment of the pharmaceutical supply chain, focusing on consistent, large-scale production rather than novel drug discovery or development. Its business is centered on a single, well-known plant-derived compound.

Cognitive DysfunctionCirculatory Disorders

Technology Platform

Specialized, GMP-compliant manufacturing process for the standardization and large-scale production of botanical Ginkgo Biloba extract as an Active Pharmaceutical Ingredient (API).

Opportunities

Continued demand for established phytopharmaceuticals in aging populations, particularly in Europe and Asia.

Opportunity to leverage its GMP certification and expertise as a trusted, long-standing supplier in the pharmaceutical-grade botanical API market.

Risk Factors

Extreme product concentration risk reliant on the regulatory and market fate of a single botanical compound.

Vulnerability to supply chain disruptions for raw plant material and competition from generic API manufacturers in lower-cost regions.

Competitive Landscape

Competes with other manufacturers of botanical APIs, particularly for Ginkgo Biloba, potentially located in Asia and Eastern Europe. Its primary competitive advantages are its long-standing history, EU-based GMP manufacturing, and integration with the Schwabe Group's vertical supply chain.

More companies in Small Molecule Drugs →More companies in Ireland →